Conjugatable ligands are designed to enhance the immune response by targeting specific receptors or pathways. They are chemically modified to allow attachment to a peptide or protein using a chemical linker, thereby enhancing stability, bioavailability, and targeting precision. Conjugatable ligands mainly include cytosolic pattern recognition receptors (PRRs), C-type lectin receptors (CLRs), Toll-like receptors (TLRs), PRR agonists, and toxoid adjuvants. Developing conjugatable ligands that target various immune receptors is essential for effective targeted therapies and vaccine delivery systems.
Product Name | Catalog | Unit Size | Price |
---|---|---|---|
Resiquimod (Imidazoquinoline compound) | CDAD24-121-T | 1 mg, 5 mg | INQUIRY |
RC-529 | CDAD24-118-T | 50 mg, 100 mg, 250 mg | INQUIRY |
Recombinant (P. fluorescens) purified tetani toxin C-terminal fragment | CDAD24-135-T | 10 μg | INQUIRY |
Recombinant purified tetani toxin Light-chain | CDAD24-134-T | 10 μg | INQUIRY |
RS 09 | CDAD24-119-T | 1 mg, 5 mg, 10 mg | INQUIRY |
RS 09 TFA | CDAD24-120-T | 1 mg, 5 mg, 10 mg | INQUIRY |
STING agonist-20 | CDAD24-129-T | 1 mg, 5 mg, 10 mg | INQUIRY |
Synthetic Monophosphoryl lipid A (MPLA) | CDAD24-114-T | 1 mg | INQUIRY |
Synthetic RWJ 21757 | CDAD24-124-T | 1 mg | INQUIRY |
Tetanus Toxoid from C. tetani purified | CDAD24-132-T | 25 µg | INQUIRY |
Zymosan A | CDAD24-097-T | 1 mg | INQUIRY |
α-Galactosylceramide (KRN7000) | CDAD24-030-T | 1 mg | INQUIRY |